# CSBR earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/CSBR) · [Earnings tab](https://www.lopjlb.com/stock/CSBR?tab=earnings) Updated: 2026-07-20T01:55:14 Quarters analyzed: 8 ## Cross-quarter narrative Across six quarters the company moved from modest Q4‑2024 revenue growth and a tentative return to adjusted EBITDA positivity toward a record FY‑2025 and FY‑2026 with multiple quarters of positive EBITDA. Early calls highlighted weak biotech R&D budgets, cancellation risk and cash‑runway pressure; subsequent quarters showed improving demand visibility as cancellations fell and large‑pharma multistudy programs grew. Gross margins swung from sub‑50% in 2024 to a peak of 61% in Q3‑2025 driven by high‑margin data licensing, then dipped with outsourced radiolabeling costs before rebounding to the low‑50s in 2026. A clear strategic shift emerged with the launch and scaling of a data‑licensing platform and a radiopharmaceutical services line, both cited as new revenue engines. Operational efficiencies and cost reductions were repeatedly delivered, underpinning margin gains. However, the funding environment remained a persistent macro headwind, and the Corellia subsidiary’s financing stayed at‑risk, limiting the pace of drug‑development investments. Overall the narrative reflects a transition from early operational and market uncertainty to a more diversified service mix, while macro funding constraints and Corellia financing continue to loom. ## Latest CallCard · Q3 Champions Oncology posted record services revenue, third straight quarter of positive adjusted EBITDA and early data‑business momentum, while noting funding timing uncertainty for Corellia and a focus on margin improvement. **Guidance:** maintained — maintained full‑year revenue growth and positive adjusted EBITDA outlook **Tone:** mgmt 0.6 · Q&A pressure 0 · divergence 0.5 delivered another quarter of strong operational performance, record services revenue and positive adjusted EBITDA; on track for full‑year growth ### Demand visibility healthy demand and stabilizing customer budgets underlying demand for our services remains healthy and customer budgets stabilize, converting bookings into revenue ### Margins / costs gross margin pressured by outsourced radiolabeling costs, expected to improve as work is brought in‑house more than $2 million of cost of sales was attributable to outsourced laboratory work; bringing this work in‑house should lift gross margin above 50% ### Capital allocation investing in data platform and Corellia while maintaining positive adjusted EBITDA continue to invest in both our data business and Corellia without dilution of Champions' shares, balancing growth and disciplined capital allocation ### Milestones - **6‑figure data deal closed** [on_track]: closed a 6‑figure data deal expected to be recognized in Q4 - **Large data deal incremental revenue** [on_track]: progressing large data deal announced in Q3 FY25 with incremental revenue expected in Q4 - **Corellia external funding round** [at_risk]: no specific timing; discussions ongoing in a challenging biotech funding environment - **Radiolabeling cost reduction** [on_track]: bringing outsourced radiolabeling work in‑house to improve margins - **PDX Bank differentiation** [delivered]: PDX Bank remains a true differentiator in the market ### Fears / risks - **Funding risk**: external financing for Corellia may be delayed given current biotech funding environment - **Revenue volatility**: services revenue can fluctuate due to timing of study progression and completion - **Margin pressure**: outsourced radiolabeling workflows increased cost of sales, affecting gross margin - **Data revenue uncertainty**: data platform revenue is nascent and will vary quarter‑to‑quarter - **Market lumpy nature**: business is somewhat lumpy with revenue fluctuations as studies move through phases ### Key quotes > “We delivered another quarter of strong operational performance, including record services revenue and our third consecutive quarter of positive adjusted EBITDA.” > “We remain on track for full year revenue growth and full year positive adjusted EBITDA while continuing to invest in both our data platform and our discovery therapeutics subsidiary.” > “While I need to reiterate that this is still early, these developments are encouraging.” > “Our core study revenue reached a record $16.6 million compared to $12.6 million in the year ago period, representing growth of approximately 32%.” > “More than $2 million of cost of sales in the quarter was attributable to outsourced laboratory work primarily related to radiolabeling workflows. As we continue bringing this work in-house, we expect these costs to decline and margins to” ## Quarter one-liners - **2026 Q3:** Champions Oncology posted record services revenue, third straight quarter of positive adjusted EBITDA and early data‑business momentum, while noting funding timing uncertainty for Corellia and a focus on margin improvement. - **2026 Q2:** Champions Oncology reports year‑over‑year revenue growth, margin expansion and progress on radiolabeling and data platform while reaffirming FY2026 positive adjusted EBITDA guidance. - **2026 Q1:** Champions Oncology Q1 FY2026 saw revenue rebound to $14 M, a return to adjusted EBITDA positivity, and progress on data and radiopharma initiatives, but margins are pressured and future growth hinges on data licensing and funding for Corellia. - **2025 Q4:** Champions Oncology turned around FY2025 with record revenue, restored profitability, launched radiopharma services and early data licensing, while management remains cautiously optimistic amid a tight biotech market. - **2025 Q3:** Champions Oncology posted record $17M revenue and $5.2M adjusted EBITDA, closed its first data licensing deal, but faces a tight biotech funding environment and uncertainty around future data deal pipeline. - **2025 Q2:** Champions Oncology reported strong Q2 FY2025 revenue growth, margin improvement and a new data‑licensing revenue stream, while noting a cautiously optimistic funding environment and ongoing capital raise for its Corellia subsidiary. - **2025 Q1:** Champions Oncology posted Q1 FY2025 revenue of $14.1M, improved gross margin to 50% and adjusted EBITDA $2M, citing operational efficiencies and a cautiously optimistic outlook amid a still‑tight funding environment. - **2024 Q4:** Q4 2024 showed modest revenue growth and a return to adjusted EBITDA positivity driven by operational improvements, but macro biotech weakness and limited guidance keep outlook uncertain. ## Theme arcs - **Demand visibility** (improving): From weak biotech budgets and high cancellations to moderate and then healthy demand as big‑pharma multistudy programs expand - **Gross margin** (improving): Margins rose from ~49% in 2024 to 61% in Q3‑2025, later pressured by outsourced radiolabeling but recovered to low‑50s in 2026 - **Data licensing business** (new): Introduced Q2‑2025, first deal delivered Q3‑2025, pipeline expanding with multiple deals by Q3‑2026 - **Radiopharma services** (new): Platform launched Q4‑2025, ongoing in‑house transition to improve margins - **Operational efficiency** (improving): Cost‑of‑sales reductions and operational improvements delivered repeatedly, supporting EBITDA - **Funding environment** (deteriorating): Biotech and pharma R&D budgets remain constrained throughout, limiting customer spend - **Corellia financing risk** (stable): Capital raise repeatedly at‑risk with no resolution by Q3‑2026 - **Cancellation risk** (resolved): High cancellation rates noted Q4‑2024, not referenced in later calls - **Customer concentration** (resolved): Early concern about reliance on top‑tier pharma faded in later updates - **AI/ML integration** (new): Announced Q3‑2025 with on‑track status, no further update indicating early stage ## Guidance path 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:maintained → 2025 Q4:maintained → 2026 Q1:vague → 2026 Q2:maintained → 2026 Q3:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/CSBR`